Omnicell, Inc. $OMCL Shares Acquired by Penserra Capital Management LLC

Penserra Capital Management LLC increased its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 264.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,215 shares of the company’s stock after acquiring an additional 6,685 shares during the quarter. Penserra Capital Management LLC’s holdings in Omnicell were worth $270,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Nicholas Company Inc. grew its position in Omnicell by 6.0% during the 2nd quarter. Nicholas Company Inc. now owns 104,488 shares of the company’s stock worth $3,072,000 after purchasing an additional 5,868 shares during the last quarter. Pier Capital LLC raised its holdings in shares of Omnicell by 81.3% in the second quarter. Pier Capital LLC now owns 176,925 shares of the company’s stock valued at $5,202,000 after buying an additional 79,348 shares during the last quarter. Arkadios Wealth Advisors boosted its stake in shares of Omnicell by 6.6% during the second quarter. Arkadios Wealth Advisors now owns 49,791 shares of the company’s stock worth $1,464,000 after buying an additional 3,086 shares during the period. Redmond Asset Management LLC grew its holdings in shares of Omnicell by 2.1% during the second quarter. Redmond Asset Management LLC now owns 144,141 shares of the company’s stock worth $4,238,000 after buying an additional 3,030 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Omnicell during the second quarter worth about $282,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Insider Transactions at Omnicell

In related news, EVP Corey J. Manley sold 3,880 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $33.25, for a total value of $129,010.00. Following the transaction, the executive vice president owned 110,653 shares in the company, valued at approximately $3,679,212.25. This trade represents a 3.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.52% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Benchmark increased their price objective on Omnicell from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Weiss Ratings restated a “sell (d+)” rating on shares of Omnicell in a research note on Wednesday, October 8th. Wells Fargo & Company increased their price target on Omnicell from $37.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, July 21st. Piper Sandler lowered their price objective on shares of Omnicell from $57.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 11th. Finally, Wall Street Zen lowered shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Omnicell presently has a consensus rating of “Hold” and a consensus target price of $42.00.

Omnicell Price Performance

Shares of Omnicell stock opened at $36.86 on Thursday. The business’s fifty day moving average price is $31.83 and its 200 day moving average price is $30.48. Omnicell, Inc. has a twelve month low of $22.66 and a twelve month high of $49.17. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.65 billion, a P/E ratio of 73.72, a PEG ratio of 6.29 and a beta of 0.95.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.